Surface plasmon resonance-based competition assay to assess the sera reactivity of variants of humanized antibodies

Journal of Immunological Methods

Volumn 268, Issue 2, 2002, Pages 197-210

  Gonzales, Noreen R ^a   Schuck, Peter ^b   Schlom, Jeffrey ^a   Kashmiri, Syed V S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CC49; Humanized antibody; Immunogenicity; Monoclonal antibody; Sera reactivity; Surface plasmon resonance

Indexed keywords

ALLOANTIBODY; LIGAND; MONOCLONAL ANTIBODY; PROTEIN;

ANTIBODY LABELING; ANTIGEN BINDING; ARTICLE; BIOSENSOR; BLOOD ANALYSIS; CASE REPORT; COMPETITIVE INHIBITION; HUMAN; IC 50; IMMUNOLOGICAL PROCEDURES; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN IMMOBILIZATION; PROTEIN PURIFICATION; SURFACE PLASMON RESONANCE; VALIDATION PROCESS;

ADSORPTION; ANIMALS; ANTIBODIES; ANTIBODIES, NEOPLASM; BINDING, COMPETITIVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN VARIABLE REGION; MICE; SURFACE PLASMON RESONANCE;

MURINAE;

EID: 0037107598     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(02)00205-3     Document Type: Article

References (38)

1. Abrantes M., Magone M.T., Boyd L.F., Schuck P. Adaptation of a surface plasmon resonance biosensor with microfluidics for use with small sample volumes and long contact times. Anal. Chem. 73:2001;2828.
2. Adamczyk M., Moore J.A., Yu Z. Application of surface plasmon resonance towards studies of low-molecular-weight antigen-antibody binding interactions. Methods. 20:2000;19.
3. Bradford M.M. A rapid and simple method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248.
4. DeNardo G.L., Schlom J., Buchsbaum D.J., Meredith R.F., O'Donoghue J.A., Sgouros G., Humm J.L., DeNardo S.J. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer. 94:2002;1332.
5. De Pascalis R., Iwahashi M., Tamura M., Padlan E.A., Gonzales N.R., Santos A.D., Giuliano M., Schuck P., Schlom J., Kashmiri S.V.S. Grafting of "abbreviated" CDRs containing specificity determining residues (SDRs) essential for ligand contact to engineer a less immunogenic humanized mAb. J. Immunol. 2002;. in press.
6. Fägerstam L.G., Frostell-Karlsson Å., Karlsson R., Persson B., Rönnberg I. Biospecific interaction analysis using surface plasmon resonance detection applied to kinetic, binding site and concentration analysis. J. Chromatogr. 597:1992;397.
7. Gilligan J.J., Schuck P., Yergey A.L. Mass spectrometry after capture and small volume elution of analyte from a surface plasmon resonance biosensor surface. Anal. Chem. 74:2002;2041.
8. Gómara M.J., Ercilla G., Alsina M.A., Haro I. Assessment of synthetic peptides for hepatitis A diagnosis using biosensor technology. J. Immunol. Methods. 246:2000;13.
9. Hearn M.T., Bethell G.S., Ayers J.S., Hancock W.S. Application of 1,1′-carbonyldiimidazole-activated agarose for the purification of proteins: II. The use of an activated matrix devoid of additional charged groups for the purification of thyroid proteins. J. Chromatogr. 185:1979;463.
10. Iwahashi M., Milenic D.E., Padlan E.A., Bei R., Schlom J., Kashmiri S.V.S. CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to Ag binding and immunogenicity. Mol. Immunol. 36:1999;1079.
11. Johnsson B., Lofas S., Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal. Biochem. 198:1991;268.
12. Kabat E.A., Wu T.T., Perry H.M., Gottesman K.S., Foeller C. Sequences of Proteins of Immunological Interests. 5th ed. 1991;U.S. Department of Health and Human Services, National Institutes of Health, Bethesda, MD. (NIH Publication no. 91-3242).
13. Kashimiri S.V.S., Shu L., Padlan E.A., Milenic D.E., Schlom J., Hand P.H. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma. 14:1995;461.
14. Kuroki M., Fernsten P.D., Wunderlich D., Colcher D., Simpson J.F., Poole D.J., Schlom J. Serological mapping of the TAG-72 tumor-associated antigen using 19 distinct monoclonal antibodies. Cancer Res. 50:1990;4872.
15. Liljeblad M., Lundblad A., Påhlsson P. Analysis of agalacto-IgG in rheumatoid arthritis using surface plasmon resonance. Glycoconj. J. 17:2000;323.
16. 1-acid glycoprotein fucosylation. Anal. Biochem. 288:2001;216.
17. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265.
18. 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. Clin. Cancer Res. 3:1997;1547.
19. Meredith R.F., Partridge E.E., Alvarez R.D., Khazaeli M.B., Plott G., Russell C.D., Wheeler R.H., Liu T., Grizzle W.E., Schlom J., LoBuglio A.F. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J. Nucl. Med. 37:1996;1491.
20. 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin. Cancer Res. 5:1999;3254s.
21. Mullet W.M., Lai E.P.C., Yeung J.M. Surface plasmon resonance-based immunoassays. Methods. 22:2000;77.
22. 177Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin. Cancer Res. 1:1995;1447.
23. Muraro R., Kuroki M., Wunderlich D., Poole D.J., Colcher D., Thor A., Greiner J.W., Simpson J.F., Molinolo A., Noguchi P., Schlom J. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res. 48:1988;4588.
24. Padlan E.A., Abergel C., Tipper J.P. Identification of specificity-determining residues in antibodies. FASEB J. 9:1995;133.
25. Pavlinkova G., Colcher D., Booth B.J.M., Goel A., Batra S.K. Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain FVs. Int. J. Cancer. 94:2001;717.
26. Ravanat C., Wiesel M.-L., Schuhler S., Dambach J., Amiral J., Cazenave J.-P. One-step assay for the determination of free protein S antigen in plasma using real-time biospecific interaction analysis. Blood Coagul. Fibrinolysis. 9:1998;333.
27. Reynolds J.C., DelVecchio S., Sakahara H., Lora M.E., Carrasquillo J.A., Neumann R.D., Larson S.M. Anti-murine response to mouse monoclonal antibodies: clinical findings and implications. Int. J. Radiat. Appl. Instrum., B. 16:1989;121.
28. Ritter G., Cohen L.S., Williams C. Jr., Richards E.C., Old L.J., Welt S. Serological analysis of human anti-human antibody response in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res. 61:2001;6851.
29. Schneider W.P., Glaser S.M., Kondas J.A., Hakimi J. The anti-idiotypic response by cynomolgus monkeys to humanized anti-Tac is primarily directed to complementarity-determining regions H1, H2 and L3. J. Immunol. 150:1993;3086.
30. Schuck P. Use of surface plasmon resonance to probe the equilibrium and dynamic aspects of interactions between biological macromolecules. Annu. Rev. Biophys. Biomol. Struct. 26:1997;541.
31. Schuck P., Boyd L.F., Andersen P.S. Measuring protein interactions by optical biosensors. Coligan J.E., Dunn B.M., Ploegh H.L., Speicher D.W., Wingfield P.T. Current Protocols in Protein Science. vol. 2:1999;20.2.1 Wiley, New York.
32. Seccamani E., Tattanelli M., Mariani M., Spranzi E., Scassellati G.A., Siccardi A.G. A simple qualitative determination of human antibodies to murine immunoglobulins (HAMA) in serum samples. Int. J. Radiat. Appl. Instrum., B. 16:1989;167.
33. Stephens S., Emtage S., Vetterlein O., Chaplin L., Bebbington C., Nesbitt A., Sopwith M., Athwal D., Novak C., Bodmer M. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology. 85:1995;668.
34. Takacs M.A., Jacobs S.J., Bordens R.M., Swanson S.J. Detection and characterization of antibodies to PEG-IFN-α2b using surface plasmon resonance. J. Interferon Cytokine Res. 19:1999;781.
35. Tamura M., Milenic D.E., Iwahashi M., Padlan E., Schlom J., Kashmiri S.V.S. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J. Immunol. 164:2000;1432.
36. van Kroonenburgh M.J., Pauwels E.K. Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases. Nucl. Med. Common. 9:1988;919.
37. van Remoortere A., van Dam G.J., Hokke C.H., van den Eijnden D.H., van Die I., Deelder A.M. Profiles of immunoglobulin M (IgM) and IgG antibodies against defined carbohydrate epitopes in sera of schistosoma-infected individuals determined by surface plasmon resonance. Infect. Immun. 69:2001;2396.
38. Winter G., Harris W.J. Humanized antibodies. Immunol. Today. 14:1993;243.